Radiofrequency ablation (RFA) is one of the most widespread ablation methods used in the treatment of small cancers of various organs, including the liver. The procedure entails the administration of a high-frequency current through single or multiple needle guided probes to the tumor site. This method is less invasive than many traditional surgical procedures, and as such has reduced morbidity and mortality. As with all procedures and clinical interventions, RFA is anyway not risk free, and carries the risk for adverse effects which most commonly include bleedings, infections, and hepatic or other organ damage.
As already mentioned, RFA is applicable for curative treatment of small tumors, so could not be called upon singlehandedly in the treatment of larger or more widespread cancers. It is common for multidisciplinary teams to recommend RFA along with other therapeutic modalities to provide evidence-based good quality personalized clinical care to liver cancer patients.
Radiofrequency tumor ablation has already been used in combination with other therapeutic interventions such as chemotherapy, immunotherapy, and radiotherapy. As to the full opportunities that RFA presents when combined with other therapies remains to be seen.
This Research Topic invites submissions which demonstrate the utilization of RFA as either monotherapy or polytherapy in benefitting patients diagnosed with primary or metastatic liver cancer. The combination therapies involving RFA may involve, but need not be limited to, combinations with chemotherapy, immunotherapy, and radiotherapy. Manuscripts may also demonstrate benefits of RFA monotherapy compared to other curative interventions, such as those concerning surgical intervention.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Radiofrequency ablation (RFA) is one of the most widespread ablation methods used in the treatment of small cancers of various organs, including the liver. The procedure entails the administration of a high-frequency current through single or multiple needle guided probes to the tumor site. This method is less invasive than many traditional surgical procedures, and as such has reduced morbidity and mortality. As with all procedures and clinical interventions, RFA is anyway not risk free, and carries the risk for adverse effects which most commonly include bleedings, infections, and hepatic or other organ damage.
As already mentioned, RFA is applicable for curative treatment of small tumors, so could not be called upon singlehandedly in the treatment of larger or more widespread cancers. It is common for multidisciplinary teams to recommend RFA along with other therapeutic modalities to provide evidence-based good quality personalized clinical care to liver cancer patients.
Radiofrequency tumor ablation has already been used in combination with other therapeutic interventions such as chemotherapy, immunotherapy, and radiotherapy. As to the full opportunities that RFA presents when combined with other therapies remains to be seen.
This Research Topic invites submissions which demonstrate the utilization of RFA as either monotherapy or polytherapy in benefitting patients diagnosed with primary or metastatic liver cancer. The combination therapies involving RFA may involve, but need not be limited to, combinations with chemotherapy, immunotherapy, and radiotherapy. Manuscripts may also demonstrate benefits of RFA monotherapy compared to other curative interventions, such as those concerning surgical intervention.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
